Zactima (vandetanib) is an orally available tyrosine kinase inhibitor (TKI) under development by AstraZeneca for the treatment of solid tumours.
Coined from ‘exact’; powerful/active sounding, suggests precision/targeted treatment, reduced side–effects and superior efficacy, easily communicated and understood.
